Loading stock data…
$2.12-0.11 (-4.93%)
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases.
Kalaris Therapeutics, Inc. in the Healthcare sector is trading at $2.12 with a market capitalization of $75M. Wall Street consensus targets $18.71 (7 analysts), implying a +782.7% move over the next 12 months. The stock is currently near its 52-week low of $2.11, remaining 63.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 14 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$12.39M↓ | -$11.83M↓ | -$10.80M↑ | -$12.74M↓ | -$12.26M |
| Net Income | -$11.52M↓ | -$10.86M↓ | -$10.00M↑ | -$11.89M↓ | -$11.35M |
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) ...